Expansion opportunities GenePlanet has a strong track record of international presence (over 35 countries) and recent acquisitions (New Era Genetics) that signal rapid geographic and capability expansion. This creates sales opportunities in new markets and with partners seeking integrated genomics solutions across diverse regions.

Enterprise partnerships The company collaborates with over 1000 medical centres, doctors, and insurance companies, indicating a robust B2B ecosystem. Targeted enterprise partnerships with clinics, hospitals, and payers could scale adoption of preventive genetic tests and integrate NIPT, cancer screening, and lifestyle DNA into standard care pathways.

Growth capital A EUR 20 million Series B funding round and ongoing top-tier investor backing suggest strong financial health and a mandate for aggressive expansion. This can be leveraged to propose large multi-country deployments, data infrastructure projects, and joint development of new tests.

Tech and data focus The tech stack includes cloud, data platforms, and delivery pipelines (SAP, DynamoDB, Metabase, RudderStack, Continuous Delivery). This indicates readiness for scalable genomics services, big data analytics, and secure data sharing—opportunities to upsell integrated data services and analytics for partners.

Commercial momentum Recognition as a fast-growing EU company and unicorn potential, along with a diverse test portfolio (NIPT, cancer screening, lifestyle DNA), positions GenePlanet well for cross-sell of new tests and bundled preventive care programs to existing medical networks and insurers.